Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;136(1):25-9.
doi: 10.1016/j.ygyno.2014.11.005. Epub 2014 Nov 8.

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

Erin K Crane  1 , Charlotte C Sun  1 , Pedro T Ramirez  1 , Kathleen M Schmeler  1 , Anais Malpica  2 , David M Gershenson  3
Affiliations

The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer

Erin K Crane et al. Gynecol Oncol. 2015 Jan.

Abstract

Objectives: We sought to determine the benefit of secondary cytoreductive surgery (SCRS) in patients with low-grade serous ovarian or peritoneal carcinoma, and whether cytoreduction to no gross residual disease affects survival.

Methods: A single institution retrospective chart review was conducted in patients with recurrent low-grade serous carcinoma who underwent SCRS between 1995 and 2012. Data including demographics, survival, chemotherapy, disease characteristics at the time of surgery, residual disease, and operative complications were collected. Overall survival (OS) and progression-free survival (PFS) were calculated. Kaplan-Meier and log-rank tests were used to examine survival outcomes.

Results: Forty-one patients met inclusion criteria. The median time between primary tumor debulking and SCRS was 33.2 months. Of 41 eligible patients who underwent SCRS, 32 (78%) had gross residual disease at the completion of secondary surgery. The median PFS for patients with no gross residual disease after SCRS was 60.3 months, compared to 10.7 months for patients with gross residual disease (p = 0.008). Median OS from diagnosis for patients with no gross residual disease after SCRS was 167.5 months compared to 88.9 months (p = 0.10). Median OS from the time of SCRS for patients with no gross residual disease was 93.6 months compared to 45.8 months (p = 0.04). Complications occurred in 61% of patients after SCRS; there were no deaths directly attributable to surgery.

Conclusion: Our results suggest a benefit to SCRS in patients with recurrent low-grade serous carcinoma. Efforts to maximally cytoreduce patients should be made as patients with no gross residual disease had a better PFS and a trend toward better OS.

Keywords: Low-grade serous ovarian cancer; Optimal cytoreduction; Secondary cytoreduction.

PubMed Disclaimer

Conflict of interest statement

The authors of this manuscript declare no conflicts of interest

Figures

Figure 1
Figure 1
Progression-free survival from the time of secondary cytoreductive surgery (p=0.008)
Figure 2
Figure 2
Overall survival from the time of secondary cytoreductive surgery (p=0.04)
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. - PubMed
    1. Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008;198(4):459 e1–458 e1. discussion e8-9. - PubMed
    1. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41–44. - PubMed
    1. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108(2):361–368. - PubMed
    1. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, et al. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol. 2007;105(3):625–629. - PubMed

Publication types